---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174540"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:00:59.248611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma reports Q2 2025 revenue of $146.6M (+19.4% YoY); GAAP net income $52.1M

## Summary
- FIRDAPSE Q2 net revenue $84.8M (+9.7% YoY); first-half 2025 net revenue $168.6M (+16.9% YoY).
- AGAMREE Q2 net revenue $27.4M (+212.9% YoY); first-half net revenue $49.4M (+398.0% YoY).
- FYCOMPA Q2 net revenue $34.3M (-6.0% YoY due to generic entry post LOE).
- Non-GAAP diluted EPS $0.68, up from $0.56 in Q2 2024; cash $652.8M, no funded debt.
- Reaffirmed FY2025 total revenue guidance of $545M to $565M.

## SEC filing metadata
- accession: 0001193125-25-174540
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/0001193125-25-174540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/d941750d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174540
- JSON: https://secwatch.observer/filing/0001193125-25-174540.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.